|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
N/A
|
National Institutes of Health
|
|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
N/A
|
National Institutes of Health
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-05
|
$312,942
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
5R01CA198015-03
|
$366,000
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
5R01CA198015-04
|
$366,000
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$755,842
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$755,842
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S1
|
$56,922
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S2
|
$165,708
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
5UM1CA173642-05
|
$2,260,718
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
|
2R01CA160495-06A1
|
$370,500
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|